Related Experiment Video
Updated: Jun 26, 2026
08:01
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Plasminogen activator inhibitor type 1 deficiency.
1Department of Clinical Medicine, Section of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. ramehta@iupui.edu
Summary
Plasminogen activator inhibitor type 1 (PAI-1) deficiency is a rare cause of bleeding disorders. Diagnosis is challenging due to limitations in current PAI-1 activity assays, hindering prevalence studies.
Area of Science:
- Hematology
- Coagulation science
- Molecular diagnostics
Background:
- Plasminogen activator inhibitor type 1 (PAI-1) regulates fibrinolysis in circulation.
- Reduced PAI-1 levels can lead to increased fibrinolysis and bleeding diathesis.
- PAI-1 deficiency is a rare but documented cause of bleeding disorders.
Purpose of the Study:
- To review the clinical presentation and diagnostic challenges of PAI-1 deficiency.
- To highlight the limitations of current diagnostic assays for PAI-1 activity.
- To discuss the management of bleeding in PAI-1 deficient individuals.
Main Methods:
- Literature review of reported PAI-1 deficiency cases.
- Analysis of diagnostic assay capabilities for PAI-1 activity and antigen.
- Discussion of clinical manifestations and treatment strategies.
Main Results:
- PAI-1 deficiency presents with mild to moderate bleeding symptoms like epistaxis and menorrhagia.
- Affected individuals rarely experience spontaneous bleeding.
- Antifibrinolytic agents are effective in managing bleeding events.
- Current PAI-1 activity assays lack sensitivity at low levels, complicating diagnosis.
- Antigen assays are only helpful for complete quantitative disorders.
Conclusions:
- Accurate diagnosis of PAI-1 deficiency is hindered by assay limitations, particularly in detecting low activity levels.
- The true prevalence of PAI-1 deficiency remains unknown due to diagnostic challenges.
- Standardized, sensitive PAI-1 activity assays are needed to improve diagnosis and determine prevalence.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:09Cytoskeletal Linker Proteins - Plakins
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...